Financial Highlights

Gilead delivered strong financial performance in 2020, reflecting the robust underlying fundamentals of our business driven by the HIV franchise and a solid contribution from Veklury®, which was developed in rapid response to the COVID-19 pandemic. We continued to expand our commercial portfolio and clinical pipeline across various therapeutic areas to drive future growth potential.

Our HIV franchise grew by 3% compared with 2019, reflecting the increase in sales of Biktarvy® and the growth of Descovy for PrEP®. Veklury sales contributed $2.8 billion in 2020. Sales of cell therapy products also grew 33% from 2019 driven by Yescarta® and the launch of Tecartus® in the United States.

In 2020, we executed 18 strategic partnerships and acquisitions, with the goal of expanding our portfolio and pipeline to encompass new opportunities.

With our strong operating cash flows, we also increased our cash dividends paid to shareholders from $3.2 billion in 2019 to $3.4 billion in 2020.

Notable highlights of Gilead’s performance in 2020 include:

- **$24.7B** Total Revenues
- **$8.2B** Cash Flows From Operating Activities
- **$7.9B** Cash, Cash Equivalents and Marketable Securities¹
- **$5.0B** Research and Development Expenses²
- **$3.4B** Cash Dividend Payments
- **$25.7B** Cash Used for Acquisitions
- **$1.6B** Share Repurchases
- **$2.5B** Debt Repayments

¹ Represents the balance as of December 31, 2020.
² Excludes acquired in-process research and development expenses of $5.9 billion.

For more information about Gilead’s 2020 financial performance, refer to our 2020 Annual Report on Form 10-K available on our website’s Investors page.